ClinicalTrials.gg
RecruitingNCT03351634BPUAUpdated Oct 29, 2026

EVALUATION OF THE SAFETY AND EFFICACY OF ADJUSTABLE CONTINENT THERAPY IN CHILDREN WITH SPINAL DYSRAPHISM.

An interventional study of Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck in Neurogenic Bladder Due to Spinal Dysraphism, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2018; still recruiting 8 years 7 months later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Study summary

Urinary continence is still a difficult goal to achieve in neurogenic bladder patients. Conservative treatment of neurogenic urinary incontinence using clean intermittent catheterization in conjunction with pharmacological therapy, notably anticholinergic medication +/- adrenergic agents, may produce continence in a variable number of patients. In other patients, reconstructive surgery of the bladder and/or bladder neck is necessary to achieve urinary continence. Surgical treatment options to increase bladder outlet resistance in patients with neurogenic bladder include injection of bulking agents around the bladder neck, bladder neck reconstruction, fascial sling procedures and Artificial Urinary Sphincter.

The Adjustable Continence Therapy system (ACT) or periurethral adjustable balloons are a minimally invasive device consisting of two volume-adjustable balloons implanted periurethrally at the bladder neck as a method of augmenting titration for urethral coaptation. Adjustable means that such system would be adaptable to the individual clinical condition.

Originally conceived and developed as a treatment for female stress urinary incontinence, the technique has been then adapted and balloons were globally developed for the use in postprostatectomy incontinence. The published success rate in male after prostatectomy and in women was respectively 56 to 92% and 60 to 83%.

The investigators hypothesize that the use of ACT for treating incontinence in children secondary to neurogenic sphincter incontinence could compress the urethra or the bladder neck, acting as an extrinsic occlusive system increasing passive and dynamic urethral and bladder resistance.

Goal of the study:

To prospectively assess the efficacy and safety of periurethral adjustable balloons in the treatment of neurogenic incontinence in children with spinal dysraphism.

Material and methods :

A prospective study will be performed at La Timone Enfants hospital and La Nord hospital in Marseille, France. Boys and girls at least at school age (5 or 6 years) with neurogenic incontinence due to outlet issues (low detrusor leak point pressure and low stress leak point pressure) with spinal dysraphism will be recruited.

The ACT balloon is an implantable medical device developed and furnished for free by Uromedica (Irvine, CA, USA). The procedure is performed under general anaesthesia using the same implantation technique as published in adult population.

02

Conditions studied

  • Neurogenic Bladder Due to Spinal Dysraphism
03

In context

Spinal Dysraphism

142 studies on the registry are indexed under Spinal Dysraphism; 39 are open to participants now.

This study's planned enrollment of 10 is below the median of 30 across 91 interventional studies indexed under Spinal Dysraphism.

Browse Spinal Dysraphism studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Boys and girls > 5 years with spinal dysraphism (occult or open)
  • Neurogenic sphincteric incontinence (leak point pressure \< 45 cm d'H20, open bladder neck during filling, urinary incontinence)
  • Normal renal function ( > 90ml/min)
  • No (or stable) upper urinary tract dilatation in ultrasound
  • In case no compliante bladder ( bladder capacity \< 50% for the age) a concomitant injection of botox endoscopically will be performed

Exclusion criteria

Exclusion Criteria:

  • under 5 years with an acquired neurogenic bladder
  • renal insufficiency (acute or chronic)
  • evolutive deterioration of the upper urinary tract (hydronephrosis)
  • active systemic or urinary tract infections
  • unmanageable detrusor instability
  • reduced bladder compliance
  • residual volume greater than 100 ml after voiding
  • bleeding disorders
  • urethral stenosis
  • who refused CIC
  • patent sacral bedsore
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Children with neurogenic incontinence with spinal dysraphism

    Device: Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck

Interventions

  • DeviceImplantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck

    The ACT system is a permanent implant designed for the correction of incontinence in patients.

06

What researchers measure

Primary outcomes

  1. Measurement of urinary continence with the Schulte-Baukloh score and 24hours pad-test

    Evaluation of urinary continence with mictional schedule and 24hours pad-test (Patients will be classified as "dry" if they will be using no pads or a single ''security pad'' per day; "significantly improved" if a reduction \>50% in pad usage (usually representing 2- 5 pads/day, depending on preoperative pad use); and little/no improvement (\>5 pads/day and \<50% improvement against baseline) and the Schulte-Baukloh score

    Time frame: 5 YEARS

Secondary outcomes

  1. Evaluation of the quality of life with the PIN-Q score

    The child will be asked to answer some items

    Time frame: 5 YEARS

07

Study locations

1 of 1 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Status
Status unknown→Recruiting
changed Oct 29, 2026
Sites
Assistance Publique Hopitaux de Marseille is now Recruiting
Oct 29, 2026
Start date
Dec 30, 2017→Mar 30, 2018 (actual)
Oct 29, 2026
Primary completion
Oct 30, 2023→Mar 30, 2027
Oct 29, 2026
Study completion
Oct 30, 2024→Jul 30, 2032
Oct 29, 2026
Contact
Study contact changed: removed c•••@ap-hm.fr. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Assistance Publique Hopitaux de Marseille · Marseille, FranceContact removed c•••@yahoo.fr
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Status unknown→Recruiting
    Assistance Publique Hopitaux de Marseille is now Recruiting
    Start date Dec 30, 2017→Mar 30, 2018 (now actual)
    Primary completion Oct 30, 2023→Mar 30, 2027
    Study completion Oct 30, 2024→Jul 30, 2032
    Contact Study contact changed: removed c•••@ap-hm.fr. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Assistance Publique Hopitaux de Marseille · Marseille, FranceContact removed c•••@yahoo.fr
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03351634
Responsible party
Sponsor
First posted
Nov 24, 2017
Start date
Mar 30, 2018
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 30, 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Alice FAURE
Contact
alice.faure@ap-hm.fr
04.91.96.81.41
Alice Faure, MD
principal investigator · ASSISTANTE PUBLIQUE HOPITAUX DE MARSEILLE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion